Emily Bodnar

H.C. Wainwright & Co.

Recent Articles about BriaCell Therapeutics Corp.

Co.'s Breast Cancer Therapy Shows Encouraging Activity 12/28/2023

BriaCell Therapeutics Corp.'s lead targeted cell therapy, when combined with the PD-1 inhibitor retifanlimab, achieved an exceptional 71% intracranial objective response rate treating brain metastases in advanced breast cancer patients, according to an H.C. Wainwright report.